Fig. 5

BZRAP1-AS1 silencing represses the angiogenesis of HCC in vivo. a Xenograft tumor growth curve. b Tumor volume and weight at the 35th day after injection. c MVD and the level of CD31 determined by immunohistochemical staining (×200). d Tumor angiogenesis in vivo determined by immunofluorescence staining (×500). *p < 0.05 vs. mice injected with oe-NC-treated cells; ^#p < 0.05 vs. mice injected with oe-THBS1-treated cells; ^&p < 0.05 vs. mice injected with sh-NC-treated cells. The data (mean ± S.D.) obeying the normal distribution homogeneity of variance among multiple groups were assessed by one-way ANOVA and repeated measures ANOVA was performed for proliferation ability at different time points followed with Tukey’s post hoc test. The experiment was repeated 3 times independently. n = 15. HCC hepatocellular carcinoma, MVD microvessel density, ANOVA analysis of variance